# Development of a biomimetic bone-on-chip to study kidney cancer metastasis : ONCOTRAP

<u>Elisa Lambert<sup>1\*</sup></u>, Ambar Lizcano Urbina<sup>1</sup>, Beatrice Cesana<sup>1</sup>, Catherine Pillet<sup>1</sup>, Joris Kaal<sup>2</sup>, Jules Heraud<sup>3</sup>, Claude Cochet<sup>1</sup>, Elisa Migliorini<sup>1</sup>, Odile Filhol<sup>1</sup> <sup>1</sup> Univ. Grenoble Alpes, INSERM 1292, CEA, UMR Biosanté, Grenoble, 38000, France - <sup>2</sup> CEA LETI DTIS, 38000 Grenoble, France - <sup>3</sup> SIS2M-LIONS CEA CNRS, UMR 3299, CEA Saclay, France \* elisa.lambert@cea.fr

### INTRODUCTION

### **BONE METASTASIS**



 $\mathbf{X}$  One of the three most frequent sites for metastasis

#### **DYNAMIC CULTURE CONDITION**

→ <u>Aim</u> : see the influence of flow and shear stress on hPDSC morphology





### RESULTS

### THE BONE NICHE

 $\rightarrow$  **Aim** : differentiate stem cells in the microfluidic device to obtain the bone niche

+ **BMP2** 

1 mm



 $\times$  Very poor prognosis (<10%), inefficient treatments

Kidney primary cancer : 30% of patients are metastatic at diagnosis

#### **METASTASIS-ON-CHIP**



### METHODS

### **CREATION OF THE BONE NICHE**

Cellular model : human Periosteum-Derived Stem Cells (hPDSC), can • differentiate into osteoblasts in the presence of **BMP2** (Bone Morphogenetic Protein)





Morphology of stem cells in static condition after 5 days ; Red : actin

Morphology of stem cells in dynamic condition with a flow rate of 3 µL/min after 5 days ; Red : actin



Osterix expression of hPDSC with soluble BMP2 after 5 days BMP2 after 5 days Green : Anti osterix antibody ; Red : actin Green : Anti osterix antibody ; Red : actin





**1 mm** 

Successful osteoblasts differentiation in the **bone chamber.** The osteoblast niche is ready after 5 days of BMP2 treatment.

### **ONCOTRAP : METASTASIS-ON-CHIP**

- $\rightarrow$  <u>Aim</u> : study the tropism of renal cancer cells towards bone
- Preliminary: a **786-O spheroid** and **hPDSC cells** have been seeded in the same microfluidic device for 31 days.







Osteoblasts







### **MICROFLUIDIC CHIP**

A microfluidic chip made of 2 chambers ( $\emptyset = 4mm$ ) in COC to welcome :

- <u>Renal chamber</u> : **786-0 mcherry** spheroid
- <u>Bone chamber</u> : monolayer **hPDSC** +/- BMP2 stained with PKH67





# CONCLUSION



#### **Cancer cells speed in the pillary channel** :

- Negative control condition  $\rightarrow$  250 µm/day
- Bone stem cells condition  $\rightarrow$  50 ± 6 µm/day
- Osteoblasts condition  $\rightarrow$  82 ± 4 µm/day

**Bone cells** seem to reduce invasion speed compare to negative control. More biological tests are expected to better explain this phenomenon.

## **PERSPECTIVE : BIOMIMETIC MATERIAL**

→ <u>Aim</u> : design a biomimetic material to present BMP2 to cells as *in vivo* on our tissues





- $\checkmark$  Cells responded to the microfluidic flow by orienting their actin filaments in the direction of the flow.
- ✓ hPDSCs are a good human cell model to built a bone niche on a microfluidic device since they differentiate into osteoblasts.
- $\checkmark$  Study of kidney cancer cells invasion in bone niche in microfluidic chip during 31 days and extraction of parameters.
- $\checkmark$  Control precisely in space the functionalization of the biomimetic platform in the bone chamber.

Acknowledgements: The MetasTRAP project has been founded by the interdisciplinary program Focus Organoïde-sur-Puces of CEA lead by the pilot committee: Carole Bresson, Anselme Perrier and Fabrice Navarro. This project is in collaboration with IMAC (Invasion Mechanisms in Angiogenesis and Cancer) and BRM (Biomimetism and Regenerative Medicine) teams of CEA-IRIG.

